1.305
price up icon0.00%   0.005
 
loading
Precedente Chiudi:
$1.31
Aprire:
$1.29
Volume 24 ore:
122.65K
Relative Volume:
0.31
Capitalizzazione di mercato:
$5.77M
Reddito:
-
Utile/perdita netta:
$-12.40M
Rapporto P/E:
-8.1563
EPS:
-0.16
Flusso di cassa netto:
$-9.08M
1 W Prestazione:
-10.27%
1M Prestazione:
-24.28%
6M Prestazione:
-79.20%
1 anno Prestazione:
-87.98%
Intervallo 1D:
Value
$1.27
$1.32
Intervallo di 1 settimana:
Value
$1.25
$1.471
Portata 52W:
Value
$1.25
$15.06

Alzamend Neuro Inc Stock (ALZN) Company Profile

Name
Nome
Alzamend Neuro Inc
Name
Telefono
844-722-6333
Name
Indirizzo
3500 LENOX RD. NE, ATLANTA
Name
Dipendente
7
Name
Cinguettio
Name
Prossima data di guadagno
2024-09-12
Name
Ultimi documenti SEC
Name
ALZN's Discussions on Twitter

Confronta ALZN con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
ALZN 1.305 5.77M 0 -12.40M -9.08M -0.16
VRTX 449.87 115.43B 10.63B -479.80M -1.35B 13.33
REGN 745.58 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 595.99 35.30B 1.86B -40.29M -1.28B -4.16
ALNY 246.18 32.04B 2.09B -332.26M 16.06M -4.14
BNTX 108.15 24.89B 3.30B -501.07M 1.03B 11.54

Alzamend Neuro Inc Stock (ALZN) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2021-10-01 Iniziato Ascendiant Capital Markets Buy

Alzamend Neuro Inc Borsa (ALZN) Ultime notizie

pulisher
Nov 19, 2024

Alzamend reports promising results for brain-targeted lithium therapy - Investing.com India

Nov 19, 2024
pulisher
Nov 19, 2024

Alzamend Neuro Announces Full Data Set from its Nonclinical Study: Comparing Brain and Plasma Lithium Exposures between AL001 and Lithium Carbonate in Alzheimer’s Transgenic Mice - Business Wire

Nov 19, 2024
pulisher
Nov 19, 2024

EXCLUSIVE: Alzamend Neuro Reveals Full Data From Nonclinical Study Of Its Lead Alzheimer's Drug Potential - Yahoo Finance

Nov 19, 2024
pulisher
Nov 15, 2024

Alzamend Neuro stock hits 52-week low at $1.39 amid sharp decline - Investing.com

Nov 15, 2024
pulisher
Oct 24, 2024

Alzamend Neuro sets trial dosage for AL001 lithium therapy - Alzheimer's News Today

Oct 24, 2024
pulisher
Oct 17, 2024

Alzamend Neuro Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s - BioSpace

Oct 17, 2024
pulisher
Oct 16, 2024

Alzamend Neuro advances Alzheimer's treatment with new lithium dose - Investing.com

Oct 16, 2024
pulisher
Oct 16, 2024

Alzamend Neuro advances Alzheimer's treatment with new lithium dose By Investing.com - Investing.com South Africa

Oct 16, 2024
pulisher
Oct 16, 2024

EXCLUSIVE: Alzamend Neuro Reveals Full Data Set From Multiple Ascending Dose Trial For Lead Candidate For Dementia Related to Alzheimer's - Yahoo Finance

Oct 16, 2024
pulisher
Oct 15, 2024

Alzamend Neuro Inc (ALZN) receives a Buy rating from Ascendiant Capital Markets - Knox Daily

Oct 15, 2024
pulisher
Oct 15, 2024

Alzamend Neuro Inc (ALZN) Performance and Fundamentals Dashboard tells a completely different story - SETE News

Oct 15, 2024
pulisher
Oct 15, 2024

Alzamend Neuro Inc (ALZN-Q) QuotePress Release - The Globe and Mail

Oct 15, 2024
pulisher
Oct 15, 2024

Alzamend Neuro regains Nasdaq compliance with equity rule By Investing.com - Investing.com UK

Oct 15, 2024
pulisher
Oct 15, 2024

Alzamend Neuro Regains Compliance with Nasdaq Listing Standards - StockTitan

Oct 15, 2024
pulisher
Oct 13, 2024

Alzamend Neuro (ALZN) Price Target Decreased by 16.00% to 21.42 - MSN

Oct 13, 2024
pulisher
Oct 10, 2024

Alzamend Neuro CEO Stephan Jackman to Participate in the Maxim Group’s Virtual Healthcare Conference - Barchart

Oct 10, 2024
pulisher
Oct 07, 2024

Nasdaq Bank Index (BANK) QuotePress Release - The Globe and Mail

Oct 07, 2024
pulisher
Oct 07, 2024

TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail

Oct 07, 2024
pulisher
Oct 03, 2024

Alzamend Neuro enters agreement for $6.5 million ATM offering - Investing.com India

Oct 03, 2024
pulisher
Oct 03, 2024

Alzamend Neuro enters agreement for $6.5 million ATM offering By Investing.com - Investing.com Australia

Oct 03, 2024
pulisher
Oct 02, 2024

Globalfoundries Inc (GFS-Q) QuotePress Release - The Globe and Mail

Oct 02, 2024
pulisher
Sep 27, 2024

Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session - MSN

Sep 27, 2024
pulisher
Sep 24, 2024

A Guide To The Risks Of Investing In Alzamend Neuro Inc (ALZN) - Knox Daily

Sep 24, 2024
pulisher
Sep 24, 2024

Alzamend Neuro Inc: Rising -96.02% from 52-Week Low, Can the Stock Stay Afloat? - The InvestChronicle

Sep 24, 2024
pulisher
Sep 16, 2024

Alzamend Neuro stock hits 52-week low at $1.81 amid market challenges - Investing.com

Sep 16, 2024
pulisher
Sep 11, 2024

Understanding the Risks of Investing in Alzamend Neuro Inc (ALZN) - Knox Daily

Sep 11, 2024
pulisher
Sep 05, 2024

New partners team up for Phase 2 trial of novel lithium therapy AL001 - Alzheimer's News Today

Sep 05, 2024
pulisher
Sep 03, 2024

Ratios Reveal: Breaking Down Alzamend Neuro Inc (ALZN)’s Financial Health - The Dwinnex

Sep 03, 2024
pulisher
Sep 03, 2024

Keeping an Eye on Alzamend Neuro Inc (ALZN) After Insider Trading Activity - Knox Daily

Sep 03, 2024
pulisher
Sep 03, 2024

Alzamend Neuro Inc (ALZN) is a good investment, but the stock may be overvalued - US Post News

Sep 03, 2024
pulisher
Aug 29, 2024

Alzamend Neuro Inc [ALZN] Records 50-Day SMA of $3.50 - Knox Daily

Aug 29, 2024
pulisher
Aug 28, 2024

It is Poised to be a Bull Market for Alzamend Neuro Inc (ALZN) - SETE News

Aug 28, 2024
pulisher
Aug 27, 2024

Investing in Alzamend Neuro Inc (ALZN): What You Must Know - Knox Daily

Aug 27, 2024
pulisher
Aug 27, 2024

Market Momentum: Alzamend Neuro Inc (ALZN) Registers a -7.47 Decrease, Closing at 2.85 - The Dwinnex

Aug 27, 2024
pulisher
Aug 26, 2024

Alzamend partners with Mass General for clinical trials - Investing.com

Aug 26, 2024
pulisher
Aug 26, 2024

Examining Alzamend Neuro Inc (ALZN) more closely is necessary - US Post News

Aug 26, 2024
pulisher
Aug 26, 2024

Alzamend partners with Mass General for clinical trials By Investing.com - Investing.com UK

Aug 26, 2024
pulisher
Aug 26, 2024

Alzamend Neuro Issues Letter to Stockholders - StockTitan

Aug 26, 2024
pulisher
Aug 23, 2024

ALZN Stock Sees Surge of Approximately 72.96% in Last Five Days - Knox Daily

Aug 23, 2024
pulisher
Aug 22, 2024

Daily Market Movement: Alzamend Neuro Inc (ALZN) Sees a -0.91 Decrease, Closing at 4.35 - The Dwinnex

Aug 22, 2024
pulisher
Aug 21, 2024

Get in on Alzamend Neuro Inc’s (ALZN) buy-in window today! - SETE News

Aug 21, 2024
pulisher
Aug 20, 2024

Alzamend Neuro Appoints Dr. Terri Hunter to Its Scientific Advisory Board - Quantisnow

Aug 20, 2024
pulisher
Aug 20, 2024

Alzamend Neuro Inc [ALZN] Stock trading around $5.85 per share: What’s Next? - The DBT News

Aug 20, 2024
pulisher
Aug 20, 2024

Crude Oil Down 2%; Alzamend Neuro Shares Spike Higher - MSN

Aug 20, 2024
pulisher
Aug 20, 2024

Why Bit Digital Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket - Benzinga

Aug 20, 2024
pulisher
Aug 19, 2024

Nvidia, AMD, Alzamend Neuro, Palo Alto Networks, Tesla: Why These 5 Stocks Are On Investors' Radars Today - Benzinga

Aug 19, 2024
pulisher
Aug 19, 2024

Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress Disorder - Quantisnow

Aug 19, 2024
pulisher
Aug 19, 2024

Analyzing the Impact of Earnings Reports on Alzamend Neuro Inc Inc. (ALZN) Price Performance - The InvestChronicle

Aug 19, 2024
pulisher
Aug 19, 2024

Nasdaq Surges 150 Points; Sonder Holdings Shares Surge - Benzinga

Aug 19, 2024
pulisher
Aug 19, 2024

Alzamend Neuro (ALZN) Could Triple from current levels and here’w why - BP Journal

Aug 19, 2024
pulisher
Aug 19, 2024

Alzamend Neuro Shares Rise on Partnership for PTSD Treatment Mid-Stage Study - MarketWatch

Aug 19, 2024

Alzamend Neuro Inc Azioni (ALZN) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Alzamend Neuro Inc Azioni (ALZN) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
AULT MILTON C III
Director
Jul 31 '24
Buy
3.74
25
93
77,193
AULT MILTON C III
Director
Apr 19 '24
Buy
0.69
1,000
688
771,699
AULT MILTON C III
Director
Apr 01 '24
Buy
0.91
334
304
770,699
AULT MILTON C III
Director
Jan 05 '24
Buy
1.06
2,000
2,127
770,365
AULT MILTON C III
Director
Jan 05 '24
Buy
1.02
5,000
5,092
768,365
AULT MILTON C III
10% Owner
Dec 26 '23
Buy
0.90
500
450
26,032
AULT MILTON C III
10% Owner
Dec 22 '23
Buy
0.92
200
185
166,866
$18.98
price up icon 1.80%
$70.68
price down icon 0.42%
$38.38
price up icon 3.49%
$369.83
price up icon 1.48%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Capitalizzazione:     |  Volume (24 ore):